Most of the phase III trials on antiepileptic drugs (AEDs) conducted to date have major methodological limitations, preventing meaningful conclusions on comparative efficacy between old and new AEDs in children. |
The superiority of the new AEDs in terms of efficacy has only been tested versus placebo. |
The commonly held opinion that new and newer AEDs have a better safety profile than old ones does not appear to be supported by evidence. |